ClinicalTrials.gg
CompletedNCT05249829Updated Aug 9, 2024Results posted

A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19

A Phase 2/3 interventional study of mRNA-1273.529 and mRNA-1273 in SARS-CoV-2, sponsored by ModernaTX, Inc.. Completed at 29 sites in United Kingdom. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-09.

Primary conditionCOVID-19Registry: Coronavirus InfectionsReclassifiedWhy we changed it
Registry
Coronavirus Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. The study's title name COVID-19, a narrower term within Coronavirus Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
3,548
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 34 studies in COVID-19 by Moderna, Inc. — 3 open to participants now, 6 under way, none of them phase 3. COVID-19 · Moderna, Inc..

Enrollment
7th of 22
3,548 · median 988
Started
2022
with 8 others
Phase 2/3
4 of 34
none open now
Registered
12th of 34
by date

Among the 34 studies in COVID-19 by Moderna, Inc., this one is the 7th largest by enrollment of the 22 interventional ones that give a count, is one of 9 that started in 2022, is one of 4 in phase 2/3, and was the 12th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 34 studies in COVID-19 by Moderna, Inc. are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 16 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in COVID-19 by Moderna, Inc., or all of them as a file.
02

Study summary

This is a 2-part study to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.529 and mRNA-1273.214 administered as a booster dose.

Read the detailed description

In Part 1, participants will be randomized in a 1:1 ratio to receive a single dose of either mRNA-1273.529 or mRNA-1273.

In Part 2, participants will be randomized in a 1:1 ratio to receive a single dose of either mRNA-1273.214 or mRNA-1273.

All participants will have previously received 2 or 3 doses of an authorized/approved COVID-19 vaccine. Participants who previously received 2 doses of a COVID-19 vaccine as a primary series will receive mRNA-1273.529, mRNA-1273.214, or mRNA-1273 as the 3rd dose, and participants who have previously received a primary series and 1 booster dose will receive mRNA-1273.529, mRNA-1273.214, or mRNA-1273 as the 4th dose (a mixed approach is acceptable). Each part will include Phase A (randomized, blinded) and Phase B (open-label, observational).

03

Conditions studied

  • SARS-CoV-2

Browse trials for

Keywords

  • Spikevax
  • mRNA-1273
  • mRNA-1273 vaccine
  • mRNA-1273.529
  • mRNA-1273.529 vaccine
  • Omicron
  • SARS-CoV-2
  • SARS-CoV-2 Vaccine
  • Coronavirus
  • Messenger RNA
  • COVID-19
  • COVID-19 Vaccine
  • Moderna
  • Multivalent Vaccine
  • Variant Strains
04

In context

COVID-19 Reclassified

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

This study's enrollment of 3,548 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.

Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants of may be enrolled in the study if the participant has a negative pregnancy test at the Screening Visit and on the day of vaccination prior to vaccine dose being administered on Day 1; has practiced adequate or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first dose (Day 1); and has agreed to continue adequate contraception through 90 days following vaccine administration.
  • Participant has received 2 prior doses of one of the following approved/authorized COVID-19 vaccines: Moderna, Pfizer/BioNTech, Oxford/AstraZeneca, Janssen. A heterologous vaccine regimen is acceptable.
  • Participants who will receive the 4th dose as part of the study must have previously received a mRNA vaccine (Moderna or Pfizer/BioNTech) as the 3rd dose of a COVID-19 vaccine. Participants who will receive the 3rd dose as part of the study may have previously received 2 doses of an approved/authorized mRNA or a non-mRNA COVID-19 vaccine (a heterologous vaccine regimen is acceptable).

Exclusion criteria

Exclusion Criteria:

  • Participant had close contact (without personal protective equipment [PPE]) as defined by the Centers for Disease Control and Prevention (CDC) in the past 14 days to someone diagnosed with SARS-CoV-2 infection or COVID-19 within 10 days of the close contact. Participants may be rescreened after 14 days provided that they remain asymptomatic.
  • Participant is acutely ill or febrile (temperature ≥ 38.0°C/100.4°F) 72 hours prior to or at the Screening Visit or Day 1.
  • Participant has tested positive for SARS-CoV-2 by an authorized/approved lateral flow/rapid antigen or polymerase chain reaction (PCR) test within 90 days of Screening.
  • Participant has received a COVID-19 vaccine within 90 days of the Screening Visit.
  • Participant has received a total of 4 doses or more of COVID-19 vaccine.
  • Participant has received a COVID-19 vaccine at a dose different from the authorized/approved dose.
  • Any medical, psychiatric, or occupational condition, including reported history of substance abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results.
  • Participant has received systemic or immune-modifying drugs for >14 days in total within 181 days prior to screening (for ≥10 milligrams [mg]/day of prednisone or equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.
  • Participant has received or plans to receive any licensed vaccine ≤28 days prior to the study injection (Day 1) or plans to receive a licensed vaccine within 28 days after the study injection (with the exception that approved seasonal influenza vaccine may be received by at least 7 days and preferably 14 days apart from the study injection).
  • Participant has received systemic immunoglobulins or blood products within 90 days prior to the Screening Visit or plans to receive during the study.
  • Participant has donated ≥450 milliliters (mL) of blood products within 28 days prior to the Screening Visit or plans to donate blood products during the study.
  • Participant has participated in an interventional clinical study within 28 days prior to the Screening Visit based on the medical history interview or plans to do so while participating in this study.

Note: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,548 participants (actual)

Study arms

  • Experimental
    Part 1: mRNA-1273.529

    Phase A: Participants will receive 1 intramuscular (IM) dose of mRNA-1273.529 on Day 1. Phase B: After Day 179, eligible participants may choose to be unblinded and to receive an additional booster outside of the study.

    Biological: mRNA-1273.529

  • Active comparator
    Part 1: mRNA-1273

    Phase A: Participants will receive 1 IM dose of mRNA-1273 on Day 1. Phase B: After Day 179, eligible participants may choose to be unblinded and to receive an additional booster outside of the study.

    Biological: mRNA-1273

  • Experimental
    Part 2: mRNA-1273.214

    Phase A: Participants will receive 1 IM dose of mRNA-1273.214 on Day 1. Phase B: After Day 85, eligible participants may choose to be unblinded and to receive an additional booster outside of the study.

    Biological: mRNA-1273.214

  • Active comparator
    Part 2: mRNA-1273

    Phase A: Participants will receive 1 IM dose of mRNA-1273 on Day 1. Phase B: After Day 85, eligible participants may choose to be unblinded and to receive an additional booster outside of the study.

    Biological: mRNA-1273

Interventions

  • BiologicalmRNA-1273.529

    Sterile liquid for injection

  • BiologicalmRNA-1273

    Sterile liquid for injection

  • BiologicalmRNA-1273.214

    Sterile liquid for injection

07

What researchers measure

Primary outcomes

  1. Part 1: Geometric Mean Concentration (GMC) of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 29

    Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as absorbance units/millilitre (AU/mL). The GMC 95% confidence interval (CI) was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.

    Time frame: Day 29 (post vaccination)

  2. Part 1: GMC of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 85

    Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.

    Time frame: Day 85 (post vaccination)

  3. Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against the B1.1.529 Strain at Day 29

    Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.

    Time frame: Day 29 (post vaccination)

  4. Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against the B1.1.529 Strain at Day 85

    Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.

    Time frame: Day 85 (post vaccination)

  5. Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against the Ancestral Strain at Day 29

    Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. The ancestral (prototype) strain was Wuhan-Hu-1. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.

    Time frame: Day 29 (post vaccination)

  6. Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against the Ancestral Strain ay Day 85

    Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. The ancestral strain was Wuhan-Hu-1. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.

    Time frame: Day 85 (post vaccination)

  7. Parts 1 and 2: Percentage of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)

    Reactogenicity refers to the occurrence and intensity of selected signs and symptoms (ARs) occurring after vaccine injection. Participants recorded such occurrences in an electronic diary on the day of study vaccine injection and for the 7 days after the day of dosing. Solicited local ARs were injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of the injection. Solicited systemic ARs were headache, fatigue, myalgia (muscle aches all over the body), arthralgia (joint aches in several joints), nausea/vomiting, chills, and fever (oral temperature). The Investigator determined if a solicited AR was also to be recorded as an adverse event (AE). A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.

    Time frame: Up to Day 8 (7 days post-vaccination)

  8. Parts 1 and 2: Number of Participants With Unsolicited AEs

    An AE was any untoward medical occurrence associated with the use of a drug/vaccine, whether or not considered related to the drug/vaccine. An unsolicited AE was any AE reported by the participant that was not specified as a solicited AR in the protocol or was specified as a solicited AR but starts outside the protocol-defined period for reporting solicited ARs (that is, 7 days after vaccination). A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.

    Time frame: Up to Day 29 (28 days post-vaccination)

  9. Parts 1 and 2: Number of Participants With Serious AEs (SAEs)

    An AE was considered an SAE if, in the view of either the investigator or Sponsor, it resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization (hospitalization or prolongation of hospitalization in the absence of a precipitating event was not in itself an SAE), resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, was a congenital anomaly/birth defect, or was a medically important event. A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.

    Time frame: Day 1 to end of study (Day 359)

  10. Parts 1 and 2: Number of Participants With Medically Attended AEs (MAAEs)

    An MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner (HCP). This would include visits to a clinic for unscheduled assessments (for example, rash assessment, abnormal laboratory follow-up, coronavirus disease 2019 \[COVID-19\]) and visits to HCPs external to the clinic (for example, urgent care, primary care physician). A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.

    Time frame: Day 1 to end of study (Day 359)

  11. Parts 1 and 2: Number of Participants With AEs Leading to Withdrawal

    An AE leading to withdrawal was defined as any AE that caused the participant to withdraw from the study, regardless of whether the decision to withdraw from the study was made by the participant or by the Investigator. A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.

    Time frame: Day 1 to end of study (Day 359)

  12. Parts 1 and 2: Number of Participants With AEs of Special Interest (AESIs)

    An AESI is an AE (serious or non serious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. Such events may have required further investigation to characterize and understand them. A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.

    Time frame: Day 1 to end of study (Day 359)

Secondary outcomes

  1. Part 1: GMC of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 29 and Day 85

    Blood samples for immunogenicity assessments were collected during protocol specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation. Superiority at Day 29 was demonstrated if the lower bound of the 99% CI of the Geometric Mean Ratio was \>1. Superiority at Day 85 was demonstrated if the lower bound of the 96% CI of the Geometric Mean Ratio was \>1.

    Time frame: Day 29 and Day 85 (post vaccination)

  2. Part 1: GMC of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 179

    Blood samples for immunogenicity assessments were collected during protocol specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.

    Time frame: Day 179 (post vaccination)

  3. Part 1: GMC of mRNA-1273.529 and mRNA-1273 Against the Ancestral Strain at Day 29, Day 85, and Day 179

    Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. The ancestral strain was Wuhan-Hu-1. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.

    Time frame: Day 29, Day 85, Day 179 (post vaccination)

  4. Parts 1 and 2: Percentage of Participants With Seroresponse Against SARS-CoV-2

    Seroresponse was defined by an increase of the GMC from pre-study vaccination (booster) below the lower limit of quantitation (LLOQ) to at least 4×LLOQ, or a 4-fold or greater rise if pre-study vaccination was ≥LLOQ. The number of participants analysed from the PPSI-Neg population include those with non-missing data at Baseline and the corresponding timepoint. 95% CI calculated using the Clopper-Pearson method.

    Time frame: Days 29, 85, 179, and 359

  5. Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against Other Variant Strains

    Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation. Other variant strains include B.1.1.7 Strain, AY.4 Strain, P.1 Strain.

    Time frame: Days 29 and 85

  6. Part 2: Percentage of Participants With Asymptomatic SARS-CoV-2 Infection Measured by Reverse Transcriptase Polymerase-chain Reaction (RT-PCR)

    Asymptomatic SARS-CoV-2 infection was defined as a positive RT-PCR test on a respiratory sample in the absence of symptoms or a positive serologic test for antinucleocapsid antibody after a negative test at time of enrollment.

    Time frame: Day 14 through the end of study (Day 359)

  7. Part 2: Percentage of Participants With Symptomatic SARS-CoV-2 Infection Measured by RT-PCR

    Symptomatic SARS-CoV-2 infection was defined 2 ways: protocol-defined COVID-19 and Center for Disease Control (CDC) COVID-19. Protocol-defined COVID-19 required at least 2 of the following systemic symptoms: fever, chills, myalgia, headache, sore throat, new olfactory and taste disorder(s), or at least 1 of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical/radiographical evidence of pneumonia, and at least 1 positive nasopharyngeal swab, nasal swab, or saliva sample (RT-PCR). CDC-defined COVID-19 was based on a positive respiratory sample (RT-PCR) and at least 1 of the following systemic or respiratory symptoms: fever, chills, cough, shortness of breath, and/or difficulty breathing, fatigue, muscle and/or body aches, headache, new loss of taste/smell, sore throat, congestion, runny nose, nausea, vomiting, or diarrhoea.

    Time frame: Day 1 through the end of study (Day 359)

  8. Part 2: Percentage of Participants With Primary Case Definition of COVID-19

    The primary case definition of COVID-19 (protocol-defined COVID-19) required the participant to have experienced at least 2 of the following systemic symptoms: fever, chills, myalgia, headache, sore throat, new olfactory and taste disorder(s), or the participant must have experienced at least 1 of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia, and must have at least 1 nasopharyngeal swab, nasal swab, or saliva sample (or respiratory sample, if hospitalized) positive for SARS-CoV-2 by RT-PCR.

    Time frame: Day 14 through the end of study (Day 359)

  9. Part 2: Percentage of Participants With Secondary Case Definition of COVID-19

    The secondary case definition of COVID-19 (CDC case definition) was based on a positive RT-PCR test on a respiratory sample and at least 1 of the following systemic or respiratory symptoms: fever, chills, cough, shortness of breath, and/or difficulty breathing, fatigue, muscle and/or body aches (not related to exercise), headache, new loss of taste/smell, sore throat, congestion, runny nose, nausea, vomiting, or diarrhoea.

    Time frame: Day 14 through the end of study (Day 359)

08

Results

Posted Aug 9, 2024

Participant flow

Participant flow — Overall Study
MilestonePart 1: mRNA-1273.529Part 1: mRNA-1273Part 2: mRNA-1273.214Part 2: mRNA-1273
Started36735714221402
Received at least 1 dose of study drug36735714221402
Completed33732013141295
Not completed3037108107
Withdrew: Participant relocation0122
Withdrew: Withdrawal by subject9174035
Withdrew: Physician decision1000
Withdrew: Lost to follow-up16165760
Withdrew: Adverse event2222
Withdrew: Covid-19 non-infection related0001
Withdrew: Protocol violation2053
Withdrew: Death0124

Outcome measures

PrimaryPart 1: Geometric Mean Concentration (GMC) of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 29

Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as absorbance units/millilitre (AU/mL). The GMC 95% confidence interval (CI) was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.

Time frame:
Day 29 (post vaccination)
Reported as:
Geometric mean · AU/mL
Part 1: Geometric Mean Concentration (GMC) of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 29
AU/mLPart 1: mRNA-1273.529Part 1: mRNA-1273
Part 1: Geometric Mean Concentration (GMC) of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 29537.7 ± 478.2302.8 ± 274.8
Statistical analysis
  • Part 1: mRNA-1273.529 vs Part 1: mRNA-1273 · Geometric mean ratio: 1.730 · 99% CI 1.493 to 2.005
PrimaryPart 1: GMC of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 85

Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.

Time frame:
Day 85 (post vaccination)
Reported as:
Geometric mean · AU/mL
Part 1: GMC of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 85
AU/mLPart 1: mRNA-1273.529Part 1: mRNA-1273
Part 1: GMC of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 85284.7 ± 248.0152.6 ± 135.1
Statistical analysis
  • Part 1: mRNA-1273.529 vs Part 1: mRNA-1273 · Geometric mean ratio: 1.763 · 96% CI 1.546 to 2.010
PrimaryPart 2: GMC of mRNA-1273.214 and mRNA-1273 Against the B1.1.529 Strain at Day 29

Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.

Time frame:
Day 29 (post vaccination)
Reported as:
Geometric mean · AU/mL
Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against the B1.1.529 Strain at Day 29
AU/mLPart 2: mRNA-1273.214Part 2: mRNA-1273
Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against the B1.1.529 Strain at Day 29465.7 ± 437.0311.0 ± 292.9
Statistical analysis
  • Part 2: mRNA-1273.214 vs Part 2: mRNA-1273 · Geometric mean ratio: 1.535 · 99% CI 1.409 to 1.672
PrimaryPart 2: GMC of mRNA-1273.214 and mRNA-1273 Against the B1.1.529 Strain at Day 85

Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.

Time frame:
Day 85 (post vaccination)
Reported as:
Geometric mean · AU/mL
Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against the B1.1.529 Strain at Day 85
AU/mLPart 2: mRNA-1273.214Part 2: mRNA-1273
Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against the B1.1.529 Strain at Day 85258.2 ± 239.3153.0 ± 142.2
Statistical analysis
  • Part 2: mRNA-1273.214 vs Part 2: mRNA-1273 · Geometric mean ratio: 1.713 · 96% CI 1.583 to 1.853
PrimaryPart 2: GMC of mRNA-1273.214 and mRNA-1273 Against the Ancestral Strain at Day 29

Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. The ancestral (prototype) strain was Wuhan-Hu-1. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.

Time frame:
Day 29 (post vaccination)
Reported as:
Geometric mean · AU/mL
Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against the Ancestral Strain at Day 29
AU/mLPart 2: mRNA-1273.214Part 2: mRNA-1273
Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against the Ancestral Strain at Day 292998.8 ± 2825.42933.6 ± 2772.3
Statistical analysis
  • Part 2: mRNA-1273.214 vs Part 2: mRNA-1273 · Geometric mean ratio: 1.048 · 99% CI 0.958 to 1.147
PrimaryPart 2: GMC of mRNA-1273.214 and mRNA-1273 Against the Ancestral Strain ay Day 85

Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. The ancestral strain was Wuhan-Hu-1. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.

Time frame:
Day 85 (post vaccination)
Reported as:
Geometric mean · AU/mL
Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against the Ancestral Strain ay Day 85
AU/mLPart 2: mRNA-1273.214Part 2: mRNA-1273
Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against the Ancestral Strain ay Day 851753.1 ± 1650.01610.2 ± 1519.6
Statistical analysis
  • Part 2: mRNA-1273.214 vs Part 2: mRNA-1273 · Geometric mean ratio: 1.104 · 96% CI 1.032 to 1.180
PrimaryParts 1 and 2: Percentage of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)

Reactogenicity refers to the occurrence and intensity of selected signs and symptoms (ARs) occurring after vaccine injection. Participants recorded such occurrences in an electronic diary on the day of study vaccine injection and for the 7 days after the day of dosing. Solicited local ARs were injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of the injection. Solicited systemic ARs were headache, fatigue, myalgia (muscle aches all over the body), arthralgia (joint aches in several joints), nausea/vomiting, chills, and fever (oral temperature). The Investigator determined if a solicited AR was also to be recorded as an adverse event (AE). A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.

Time frame:
Up to Day 8 (7 days post-vaccination)
Reported as:
Number · percentage of participants
Parts 1 and 2: Percentage of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)
percentage of participantsPart 1: mRNA-1273.529Part 1: mRNA-1273Part 2: mRNA-1273.214Part 2: mRNA-1273
Any Solicited Local ARs84.5 ± 80.489.1 ± 85.483.6 ± 81.689.9 ± 88.2
Any Solicited Systemic ARs69.8 ± 64.874.2 ± 69.470.2 ± 67.775.3 ± 73.0
PrimaryParts 1 and 2: Number of Participants With Unsolicited AEs

An AE was any untoward medical occurrence associated with the use of a drug/vaccine, whether or not considered related to the drug/vaccine. An unsolicited AE was any AE reported by the participant that was not specified as a solicited AR in the protocol or was specified as a solicited AR but starts outside the protocol-defined period for reporting solicited ARs (that is, 7 days after vaccination). A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.

Time frame:
Up to Day 29 (28 days post-vaccination)
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Participants With Unsolicited AEs
ParticipantsPart 1: mRNA-1273.529Part 1: mRNA-1273Part 2: mRNA-1273.214Part 2: mRNA-1273
Parts 1 and 2: Number of Participants With Unsolicited AEs142124442429
PrimaryParts 1 and 2: Number of Participants With Serious AEs (SAEs)

An AE was considered an SAE if, in the view of either the investigator or Sponsor, it resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization (hospitalization or prolongation of hospitalization in the absence of a precipitating event was not in itself an SAE), resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, was a congenital anomaly/birth defect, or was a medically important event. A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.

Time frame:
Day 1 to end of study (Day 359)
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Participants With Serious AEs (SAEs)
ParticipantsPart 1: mRNA-1273.529Part 1: mRNA-1273Part 2: mRNA-1273.214Part 2: mRNA-1273
Parts 1 and 2: Number of Participants With Serious AEs (SAEs)20136072
PrimaryParts 1 and 2: Number of Participants With Medically Attended AEs (MAAEs)

An MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner (HCP). This would include visits to a clinic for unscheduled assessments (for example, rash assessment, abnormal laboratory follow-up, coronavirus disease 2019 \[COVID-19\]) and visits to HCPs external to the clinic (for example, urgent care, primary care physician). A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.

Time frame:
Day 1 to end of study (Day 359)
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Participants With Medically Attended AEs (MAAEs)
ParticipantsPart 1: mRNA-1273.529Part 1: mRNA-1273Part 2: mRNA-1273.214Part 2: mRNA-1273
Parts 1 and 2: Number of Participants With Medically Attended AEs (MAAEs)242257956964
PrimaryParts 1 and 2: Number of Participants With AEs Leading to Withdrawal

An AE leading to withdrawal was defined as any AE that caused the participant to withdraw from the study, regardless of whether the decision to withdraw from the study was made by the participant or by the Investigator. A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.

Time frame:
Day 1 to end of study (Day 359)
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Participants With AEs Leading to Withdrawal
ParticipantsPart 1: mRNA-1273.529Part 1: mRNA-1273Part 2: mRNA-1273.214Part 2: mRNA-1273
Parts 1 and 2: Number of Participants With AEs Leading to Withdrawal2336
PrimaryParts 1 and 2: Number of Participants With AEs of Special Interest (AESIs)

An AESI is an AE (serious or non serious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. Such events may have required further investigation to characterize and understand them. A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.

Time frame:
Day 1 to end of study (Day 359)
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Participants With AEs of Special Interest (AESIs)
ParticipantsPart 1: mRNA-1273.529Part 1: mRNA-1273Part 2: mRNA-1273.214Part 2: mRNA-1273
Parts 1 and 2: Number of Participants With AEs of Special Interest (AESIs)42286060
SecondaryPart 1: GMC of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 29 and Day 85

Blood samples for immunogenicity assessments were collected during protocol specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation. Superiority at Day 29 was demonstrated if the lower bound of the 99% CI of the Geometric Mean Ratio was \>1. Superiority at Day 85 was demonstrated if the lower bound of the 96% CI of the Geometric Mean Ratio was \>1.

Time frame:
Day 29 and Day 85 (post vaccination)
Reported as:
Geometric mean · AU/mL
Part 1: GMC of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 29 and Day 85
AU/mLPart 1: mRNA-1273.529Part 1: mRNA-1273
Day 29537.7 (478.2 to 604.6)302.8 (274.8 to 333.6)
Day 85284.7 (248.0 to 326.7)152.6 (135.1 to 172.3)
Statistical analysis
  • Part 1: mRNA-1273.529 vs Part 1: mRNA-1273 · Geometric mean ratio: 1.730 · 99% CI 1.493 to 2.005
  • Part 1: mRNA-1273.529 vs Part 1: mRNA-1273 · Geometric mean ratio: 1.763 · 96% CI 1.546 to 2.010
SecondaryPart 1: GMC of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 179

Blood samples for immunogenicity assessments were collected during protocol specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.

Time frame:
Day 179 (post vaccination)
Reported as:
Geometric mean · AU/mL
Part 1: GMC of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 179
AU/mLPart 1: mRNA-1273.529Part 1: mRNA-1273
Part 1: GMC of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 179144.3 ± 119.470.1 ± 59.0
SecondaryPart 1: GMC of mRNA-1273.529 and mRNA-1273 Against the Ancestral Strain at Day 29, Day 85, and Day 179

Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. The ancestral strain was Wuhan-Hu-1. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.

Time frame:
Day 29, Day 85, Day 179 (post vaccination)
Reported as:
Geometric mean · AU/mL
Part 1: GMC of mRNA-1273.529 and mRNA-1273 Against the Ancestral Strain at Day 29, Day 85, and Day 179
AU/mLPart 1: mRNA-1273.529Part 1: mRNA-1273
Day 292699.7 (2431.3 to 2997.7)3020.6 (2776.5 to 3286.2)
Day 851401.2 (1236.9 to 1587.4)1559.4 (1401.2 to 1735.5)
Day 179734.6 (621.8 to 867.9)747.6 (644.1 to 867.7)
SecondaryParts 1 and 2: Percentage of Participants With Seroresponse Against SARS-CoV-2

Seroresponse was defined by an increase of the GMC from pre-study vaccination (booster) below the lower limit of quantitation (LLOQ) to at least 4×LLOQ, or a 4-fold or greater rise if pre-study vaccination was ≥LLOQ. The number of participants analysed from the PPSI-Neg population include those with non-missing data at Baseline and the corresponding timepoint. 95% CI calculated using the Clopper-Pearson method.

Time frame:
Days 29, 85, 179, and 359
Reported as:
Number · percentage of participants
Parts 1 and 2: Percentage of Participants With Seroresponse Against SARS-CoV-2
percentage of participantsPart 1: mRNA-1273.529Part 1: mRNA-1273Part 2: mRNA-1273.214Part 2: mRNA-1273
Day 29 - B.1.1.529 Strain83.2 (78.2 to 87.4)55.2 (49.2 to 61.2)84.7 (82.3 to 86.9)70.4 (67.2 to 73.3)
Day 85 - B.1.1.529 Strain48.3 (41.7 to 54.9)15.9 (11.4 to 21.4)60.6 (57.0 to 64.1)32.3 (28.8 to 35.9)
Day 179 - B.1.1.529 Strain18.1 (12.5 to 25.0)2.9 (0.8 to 7.3)37.5 (33.5 to 41.8)25.8 (22.1 to 29.9)
Day 359 - B.1.1.529 Strain36.5 (25.6 to 48.5)26.2 (15.8 to 39.1)32.5 (27.1 to 38.3)25.1 (19.9 to 30.9)
Day 29 - Ancestral Strain43.1 (37.1 to 49.2)59.0 (52.9 to 65.0)70.9 (67.9 to 73.8)68.4 (65.2 to 71.5)
Day 85 - Ancestral Strain14.3 (10.0 to 19.5)21.8 (16.6 to 27.7)38.8 (35.3 to 42.4)33.4 (29.8 to 37.1)
Day 179 - Ancestral Strain2.5 (0.7 to 6.4)6.1 (2.7 to 11.6)25.0 (21.4 to 29.0)23.8 (20.1 to 27.9)
Day 359 - Ancestral Strain2.7 (0.3 to 9.5)8.2 (2.7 to 18.1)8.9 (5.9 to 12.9)12.6 (8.7 to 17.3)
SecondaryPart 2: GMC of mRNA-1273.214 and mRNA-1273 Against Other Variant Strains

Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation. Other variant strains include B.1.1.7 Strain, AY.4 Strain, P.1 Strain.

Time frame:
Days 29 and 85
Reported as:
Geometric mean · AU/mL
Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against Other Variant Strains
AU/mLPart 2: mRNA-1273.214Part 2: mRNA-1273
Day 29 - B.1.1.7 Strain236533.1 (227116.7 to 246340.0)225834.1 (216536.7 to 235530.8)
Day 85 - B.1.1.7 Strain133951.9 (127594.4 to 140626.1)124778.3 (118785.1 to 131073.9)
Day 29 - AY.4 Strain244715.5 (234951.9 to 254884.8)236066.3 (226310.8 to 246242.3)
Day 85 - AY.4 Strain134119.3 (127672.7 to 140891.4)127263.6 (121106.4 to 133733.8)
Day 29 - P.1 Strain182396.9 (175235 to 189850.9)175216.7 (168018.0 to 182723.9)
Day 85 - P.1 Strain103438.9 (98607.6 to 108506.8)97927.0 (93264.0 to 102823.2)
SecondaryPart 2: Percentage of Participants With Asymptomatic SARS-CoV-2 Infection Measured by Reverse Transcriptase Polymerase-chain Reaction (RT-PCR)

Asymptomatic SARS-CoV-2 infection was defined as a positive RT-PCR test on a respiratory sample in the absence of symptoms or a positive serologic test for antinucleocapsid antibody after a negative test at time of enrollment.

Time frame:
Day 14 through the end of study (Day 359)
Reported as:
Number · percentage of participants
Part 2: Percentage of Participants With Asymptomatic SARS-CoV-2 Infection Measured by Reverse Transcriptase Polymerase-chain Reaction (RT-PCR)
percentage of participantsPart 2: mRNA-1273.214Part 2: mRNA-1273
Part 2: Percentage of Participants With Asymptomatic SARS-CoV-2 Infection Measured by Reverse Transcriptase Polymerase-chain Reaction (RT-PCR)16.917.7
SecondaryPart 2: Percentage of Participants With Symptomatic SARS-CoV-2 Infection Measured by RT-PCR

Symptomatic SARS-CoV-2 infection was defined 2 ways: protocol-defined COVID-19 and Center for Disease Control (CDC) COVID-19. Protocol-defined COVID-19 required at least 2 of the following systemic symptoms: fever, chills, myalgia, headache, sore throat, new olfactory and taste disorder(s), or at least 1 of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical/radiographical evidence of pneumonia, and at least 1 positive nasopharyngeal swab, nasal swab, or saliva sample (RT-PCR). CDC-defined COVID-19 was based on a positive respiratory sample (RT-PCR) and at least 1 of the following systemic or respiratory symptoms: fever, chills, cough, shortness of breath, and/or difficulty breathing, fatigue, muscle and/or body aches, headache, new loss of taste/smell, sore throat, congestion, runny nose, nausea, vomiting, or diarrhoea.

Time frame:
Day 1 through the end of study (Day 359)
Reported as:
Number · percentage of participants
Part 2: Percentage of Participants With Symptomatic SARS-CoV-2 Infection Measured by RT-PCR
percentage of participantsPart 2: mRNA-1273.214Part 2: mRNA-1273
Part 2: Percentage of Participants With Symptomatic SARS-CoV-2 Infection Measured by RT-PCR50.848.6
SecondaryPart 2: Percentage of Participants With Primary Case Definition of COVID-19

The primary case definition of COVID-19 (protocol-defined COVID-19) required the participant to have experienced at least 2 of the following systemic symptoms: fever, chills, myalgia, headache, sore throat, new olfactory and taste disorder(s), or the participant must have experienced at least 1 of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia, and must have at least 1 nasopharyngeal swab, nasal swab, or saliva sample (or respiratory sample, if hospitalized) positive for SARS-CoV-2 by RT-PCR.

Time frame:
Day 14 through the end of study (Day 359)
Reported as:
Number · percentage of participants
Part 2: Percentage of Participants With Primary Case Definition of COVID-19
percentage of participantsPart 2: mRNA-1273.214Part 2: mRNA-1273
Part 2: Percentage of Participants With Primary Case Definition of COVID-1930.529.1
SecondaryPart 2: Percentage of Participants With Secondary Case Definition of COVID-19

The secondary case definition of COVID-19 (CDC case definition) was based on a positive RT-PCR test on a respiratory sample and at least 1 of the following systemic or respiratory symptoms: fever, chills, cough, shortness of breath, and/or difficulty breathing, fatigue, muscle and/or body aches (not related to exercise), headache, new loss of taste/smell, sore throat, congestion, runny nose, nausea, vomiting, or diarrhoea.

Time frame:
Day 14 through the end of study (Day 359)
Reported as:
Number · percentage of participants
Part 2: Percentage of Participants With Secondary Case Definition of COVID-19
percentage of participantsPart 2: mRNA-1273.214Part 2: mRNA-1273
Part 2: Percentage of Participants With Secondary Case Definition of COVID-1933.530.9

Adverse events

Collected over Day 1 to end of study (Day 359). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: mRNA-1273.5290/367 (0%)20/367 (5.4%)68/367 (18.5%)
Part 1: mRNA-12731/357 (0.3%)13/357 (3.6%)70/357 (19.6%)
Part 2: mRNA-1273.2142/1,422 (0.1%)60/1,422 (4.2%)207/1,422 (14.6%)
Part 2: mRNA-12734/1,402 (0.3%)72/1,402 (5.1%)198/1,402 (14.1%)
Most frequent serious events
Showing 10 of 155
Most frequent serious events
EventPart 1: mRNA-1273.529Part 1: mRNA-1273Part 2: mRNA-1273.214Part 2: mRNA-1273
PneumoniaInfections and infestations0/3672/3572/14221/1402
Myocardial infarctionCardiac disorders2/3670/3571/14220/1402
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/3670/3572/14224/1402
Sinus tachycardiaCardiac disorders0/3671/3570/14220/1402
DiverticulitisInfections and infestations0/3671/3570/14221/1402
Infective exacerbation of chronic obstructive airways diseaseInfections and infestations0/3671/3570/14220/1402
Sternal fractureInjury, poisoning and procedural complications0/3671/3570/14220/1402
Brain neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3671/3570/14220/1402
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3671/3572/14220/1402
Small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3671/3570/14220/1402
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPart 1: mRNA-1273.529Part 1: mRNA-1273Part 2: mRNA-1273.214Part 2: mRNA-1273
COVID-19Infections and infestations28/36730/35760/142251/1402
Upper respiratory tract infectionInfections and infestations15/3679/3575/142212/1402
HeadacheNervous system disorders6/3679/35740/142229/1402
NasopharyngitisInfections and infestations3/3672/35726/142219/1402
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/3675/35722/142224/1402
Nasal congestionRespiratory, thoracic and mediastinal disorders6/3670/3574/14226/1402
DiarrhoeaGastrointestinal disorders1/3675/35716/142212/1402
Seasonal allergyImmune system disorders1/3673/35711/142219/1402
FatigueGeneral disorders4/3674/35719/142210/1402
NauseaGastrointestinal disorders0/3674/3575/14224/1402

Baseline characteristics

The Safety Set included all randomized participants who received the study vaccine. Participants were included in the study vaccine arm that they actually received.

Age, Customized
Age, Customized(participants)Part 1: mRNA-1273.529Part 1: mRNA-1273Part 2: mRNA-1273.214Part 2: mRNA-1273Total
>=16 and <65 Years2412359459352356
>=65 Years1261224774671192
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: mRNA-1273.529Part 1: mRNA-1273Part 2: mRNA-1273.214Part 2: mRNA-1273Total
Female2002026956941791
Male1671557277081757
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Part 1: mRNA-1273.529Part 1: mRNA-1273Part 2: mRNA-1273.214Part 2: mRNA-1273Total
White353335134713133348
Mixed or Multiple Ethnic Groups35212756
Asian or Asian British1010314192
Black, African, Caribbean, or Black British006612
Other Ethnic Group154717
Not Reported0211720
Unknown00213
09

Study locations

29 sites
  • Aberdeen Royal Infirmary - PPDS
    Aberdeen, Aberdeenshire AB25 2ZD, United Kingdom
  • Southmead Hospital
    Bristol, Avon BS10 5NB, United Kingdom
  • Wansford and Kingscliffe Practice
    Wansford, Cambridgeshire PE8 6PL, United Kingdom
  • Halton General Hospital
    Runcorn, Cheshire WA7 2DA, United Kingdom
  • The James Cook University Hospital
    Middlesbrough, Cleveland TS4 3BW, United Kingdom
  • Royal Cornwall Hospital
    Truro, Cornwall TR1 3LJ, United Kingdom
  • Royal Devon and Exeter Hospital NHS Trust
    Exeter, Devon EX2 5DW, United Kingdom
  • Royal Bournemouth Hospital
    Bournemouth, Dorset BH7 7DW, United Kingdom
  • Gloucester Royal Hospital
    Gloucester, Gloucestershire GL1 3NN, United Kingdom
  • Portsmouth Research Hub
    Portsmouth, Hampshire PO1 3HN, United Kingdom
  • Fylde Coast Clinical Research
    Blackpool, Lancashire FY3 7EN, United Kingdom
  • Leicester General Hospital
    Leicester, Leicestershire LE5 4PW, United Kingdom
  • Salford Royal Hospital - PPDS
    Salford, Manchester, United Kingdom
  • University College London Hospitals Covid-19 Vaccine Centre
    London, Middlesex WC1E 6EB, United Kingdom
  • Castle Hill Hospital
    Hull, North Humberside HU16 5JQ, United Kingdom
  • The Princess Royal Hospital
    Telford, Shropshire TF1 6TF, United Kingdom
  • Royal United Hospital
    Bath, Somerset BA1 3NG, United Kingdom
  • Sheffield/Northern General Hospital
    Sheffield, South Yorkshire S5 7AU, United Kingdom
  • Royal Glamorgan Hospital - PPDS
    Pontyclun, Wales CF72 8XR, United Kingdom
  • Bradford Institute for Health Research
    Bradford, West Yorkshire BD9 6RJ, United Kingdom
  • Great Western Hospital
    Swindon, Wiltshire SN3 6BB, United Kingdom
  • Queen Elizabeth Hospital
    Birmingham, B15 2TH, United Kingdom
  • Barts Hospital
    London, EC1A 7BE, United Kingdom
  • Royal Free Hospital
    London, NW3 2QG, United Kingdom
  • Kings College Hospital
    London, SE5 9RS, United Kingdom
  • Chelsea and Westminster Hospital
    London, SW10 9NH, United Kingdom
  • St. George's Hospital
    London, SW17 0RE, United Kingdom
  • Royal Victoria Infirmary
    Newcastle upon Tyne, NE1 4LP, United Kingdom
  • Derriford Hospital
    Plymouth, PL6 8DH, United Kingdom
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Jun 2023, 16 months.

Results were first posted in Aug 2024, 1 year 1 month after primary completion.

Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 16 months is above that.

Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2022
First posted
Feb 22, 2022
StartActual
Feb 16, 2022
Primary completionActual
Jun 23, 2023
CompletionActual
Jun 23, 2023
Results first posted
Aug 9, 2024
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT05249829
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Feb 22, 2022
Start date
Feb 16, 2022
Primary completion
Jun 23, 2023
Completion
Jun 23, 2023
Results posted
Aug 9, 2024
Last update
Aug 9, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA-1273.214 COVID-19 vaccine

Start the discussion